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Abstract
Background: The Human T Lymphotropic Virus type 1 (HTLV-1) subtype C is endemic to central Australia where
each of the major sequelae of HTLV-1 infection has been documented in the socially disadvantaged Indigenous
population. Nevertheless, available epidemiological information relating to HTLV-1c infection is very limited, risk
factors for transmission are unknown and no coordinated program has been implemented to reduce transmission
among Indigenous Australians. Identifying risk factors for HTLV-1 infection is essential to direct strategies that could
control HTLV-1 transmission.
Methods: Risk factors for HTLV-1 infection were retrospectively determined for a cohort of Indigenous Australians
who were tested for HTLV-1 at Alice Springs Hospital (ASH), 1st January 2000 to 30th June 2013. Demographic
details were obtained from the ASH patient management database and the results of tests for sexually transmitted
infections (STI) were obtained from the ASH pathology database.
Results: Among 1889 Indigenous patients whose HTLV-1 serostatus was known, 635 (33.6 %) were HTLV-1 Western
blot positive. Only one of 77 (1.3 %) children tested was HTLV-1 infected. Thereafter, rates progressively increased
with age (15–29 years, 17.3 %; 30–49 years, 36.2 %; 50–64 years, 41.7 %) reaching 48.5 % among men aged 50–64
years. In a multivariable model, increasing age (OR, 1.04; 95 % CI, 1.03–1.04), male gender (OR, 1.41; 95 % CI, 1.08–1.
85), residence in the south (OR, 10.7; 95 % CI, 7.4–15.6) or west (OR, 4.4; 95 % CI, 3.1–6.3) of central Australia and
previous STI (OR, 1.42; 95 % CI, 1.04–1.95) were associated with HTLV-1 infection. Infection was acquired by three of
351 adults who were tested more than once during the study period (seroconversion rate, 0.24 (95 % CI = 0.18–2.48)
per 100 person-years).
Conclusions: This study confirms that HTLV-1 is highly endemic to central Australia. Although childhood infection was
documented, HTLV-1 infection in adults was closely associated with increasing age, male gender and STI history.
Multiple modes of transmission are therefore likely to contribute to high rates of HTLV-1 infection in the Indigenous
Australian population. Future strategies to control HTLV-1 transmission in this population require careful community
engagement, cultural understanding and Indigenous leadership.
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Background
The Human T Lymphotropic Virus type 1 (HTLV-1) is
an oncogenic retrovirus that preferentially infects CD4+
T cells [1]. At least 5–10 million HTLV-1 infected people
reside in clusters of high endemicity worldwide [2]. One
such endemic focus is present in central Australia where
infection with the Australo-Melanesian HTLV-1 subtype
C is prevalent [3]. In less than 10 % of cases, HTLV-1 in-
fection is complicated by sequelae that include a rapidly
progressive Adult T cell Leukemia/Lymphoma (ATLL)
[1, 4] and inflammatory disorders, such as HTLV-1 asso-
ciated myelopathy/tropical spastic paraparesis (HAM/
TSP) [1]. In resource poor areas, infection with other
pathogens also contribute to HTLV-1 related morbidity
and mortality [5]. The virus is closely cell associated and
transmission typically follows exposure to infected lym-
phocytes in blood, through breast-feeding or sexual
intercourse [1]. Infection rates generally increase with
age, particularly among women who are thought to be at
greatest risk of sexual transmission [1].
HTLV-1 was first found to be endemic to central
Australia in 1988 [6] and this was later shown to be a
unique variant of HTLV-1 subtype C [3]. Each of the
major recognised complications of HTLV-1 infection
have now been reported from this region [4, 5]. These
include ATLL [4], HAM/TSP [5, 7], infective dermatitis
[8], strongyloidiasis [9], HTLV-1 associated pulmonary
disease [5, 10] and crusted scabies [11, 12]. Nevertheless,
no coordinated program has been implemented to in-
form Indigenous Australians of the risks posed by
HTLV-1 infection or to prevent viral transmission in this
population and HTLV-1 testing is not included in
routine antenatal screening [13]. The development of
strategies to control HTLV-1 transmission in remote
Australia is hampered by limited epidemiological data.
Determining HTLV-1 seroprevalence rates in the small
communities that are scattered across central Australia,
an area exceeding 1 million km2 (Fig. 1), is logistically
difficult. Indeed, published data are currently available
from only two small community-based studies that in-
cluded 36 [14] and 131 [6] central Australian subjects
and neither study was designed to identify risk factors
for HTLV-1 transmission. In endemic areas, such as
south-western Japan, mother-to-child transmission has
been demonstrated to be the primary mode of trans-
mission [15] and this is assumed to be the case in
Australia [16]. The present study was therefore com-
menced to provide some insights into the epidemiology of
HTLV-1c infection in central Australia from a large
hospital-based cohort. Our analysis strengthens previous
findings regarding seropositivity rates according to place
of residence [5, 16], defines risk according to age and gen-
der and identifies possible risk factors for horizontal
transmission.
Methods
Study setting
All Indigenous children (aged <15 years) and adults
(aged ≥15 years) who attended Alice Springs Hospital
(ASH) between 1stJanuary 2000 and 30th June 2013
who had an HTLV-1 screening test performed were
identified from hospital pathology records. Among
1945 subjects for whom a screening test was per-
formed, HTLV-1 serostatus could be confirmed for
1889 subjects and these were included in the final
epidemiological analysis (see flowchart; Fig. 2). The
cohort includes patients who were tested: i) when
clinically indicated to investigate the aetiology of con-
ditions that are thought to be HTLV-1 associated
(Group 1, n = 1431), ii) as part of a blood borne virus
(BBV) surveillance program among patients receiving
haemodialysis (Group 2, n = 334) and iii) after enroll-
ment as subjects without current clinical evidence of
HTLV-1 associated conditions in HTLV-1 pathogen-
esis studies (Group 3, n = 124). Conditions that are
associated with HTLV-1 infection for which HTLV-1
serology is ordered at ASH include haematological
malignancies, neurological disorders, strongyloidiasis,
chronic lung disease and dermatological conditions.
However, the test is most often ordered to accompany
strongyloides serology due to concerns that HTLV-1
coinfected patients are more likely to fail therapy and
to develop complicated strongyloidiasis [5]. Demo-
graphic data including ethnicity, place of residence
and dates of birth and death were obtained from the
ASH patient management system. Results of tests for
sexually transmitted infections (STIs) were recorded
from the hospital pathology database for adults aged
15–45 years for whom such tests are routinely or-
dered at ASH in the setting of genitourinary symp-
toms. These included nucleic acid amplification tests
(NAAT) for Chlamydia trachomatis and Neisseria
gonorrhoeae and specific tests for syphilis (fluorescent
treponemal antibody tests and Treponema pallidum
particle agglutination tests).
Residence
Place of residence was categorized as i) remote
(>80 km from Alice Springs), ii) Alice Springs town
camp and iii) urban (resident in Alice Springs, but
not in a town camp). Remote residence was further
divided into quadrants (north, south, east and west)
relative to Alice Springs. Central Australian resi-
dence was defined as residence in the Alice Springs
Municipality, Central Desert Shire and MacDonnell
Shires of the Northern Territory, the Ngaanyatjarraku
shire of Western Australia and the Anangu Pitjantjatjara
Yankunyatjara (APY) lands of South Australia
(Fig. 1).
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Estimating the number of infants at risk
The number of live infants born to Indigenous mothers
at ASH for the years 2010–12, the dates of birth and
place of maternal residence were obtained from the
ASH patient management database. An estimate of the
number of infants at risk of mother-to-child HTLV-1 ex-
posure was then calculated by multiplying the total
number of infants born to mothers from each area by
HTLV-1 seropositivity rates for women aged 15–40 years
who resided in the same region.
HTLV-1 serologic studies
Samples were initially screened at the Royal Darwin
Hospital (RDH) or Institut Pasteur, Paris, using the
Serodia HTLV-1 particle agglutination assay (Fujirebio,
Japan) and Murex HTLV-I + II test kit (Murex Diagnostics,
Dartford, UK). After November 2008, HTLV-1 screen-
ing at the RDH was with the Architect rHTLV-I/II
assay. HTLV-1 serostatus was then confirmed by
Western blot (HTLV Blot 2.4, MP Diagnostics) accord-
ing to the kit manufacturer’s criteria at the National
Serological Reference Laboratory (NRL), Melbourne, or
Institut Pasteur, Paris. Attempts were made to confirm
HTLV-1 infection for subjects with indeterminate
Western blot results using HTLV-1 polymerase chain
reaction (PCR) at the NRL. Primers and probes were
designed to target a highly conserved 88 bp fragment
of the gag gene in the p19 coding region of the
Fig. 1 a. Map showing the area served by Alice Springs Hospital (yellow), which includes the Anangu Pitjantjatjara Yankunyatjara (APY) lands of
South Australia (A), the Ngaanyatjarraku shire of West Australia (B) and the Central Desert Shire and MacDonnell Shires of the Northern Territory
(C). b. Detailed map of central Australia showing the location of the two major population centres, Tenant Creek and Alice Springs
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Australo-Melanesian HTLV-1 subtype C. The sequence of
the forward primer was AGT TCG GAG CTC AGG TCG
AGA, the reverse primer was AGC AAG CAG GGT
CAG GCA AAG and the probe was [6FAM]-
GTCCGGCGCTCCCTTAGAGCC-[BHQ1] labeled with
fluorophor FAM and Black Hole Quencher 1.
HTLV-1 Screening
Performed
1945
HTLV-1 + Screening Test
691
Referred for HTLV-1 WB
672
Insufficient Samples1
19
HTLV-1 WB +
629
HTLV-1 WB Indeterminate
43
HTLV-1 PCR +
6
PCR not possible2
37
HTLV-1 Negative
1254
HTLV-1 Positive
635
Fig. 2 Flow diagram showing reasons for excluding patients from analysis. 1945 subjects were initially screened for HTLV-1 infection using serological
tests. In 56 cases (Group 1, 48; Group 2, 4; Group 3, 4), initial serological screening tests were positive, but subjects were excluded because confirmatory
testing could not be performed. In 19 cases confirmatory Western blot tests could not be performed because insufficient sample remained after the
initial screening tests. In a further 37 cases, Western blots were indeterminate, but an appropriate sample for HTLV-1 PCR could not be collected
because patients had returned to their remote communities before the Western blot result was available to clinicians. Thus, 1889 subjects were
included in the final analysis. Abbreviations: HTLV-1+, positive HTLV-1 serological screening test; HTLV-1 WB+, positive HTLV-1 Western blot test; PCR,
polymerase chain reaction; WB, Western blot
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Statistics
All analyses were performed using Stata software version
13.0 (StataCorp, Texas, USA). Comparison of patient
characteristics between HTLV-1 infected and HTLV-1
uninfected subjects was performed using chi-squared
tests of association, independent t-tests, or Mann-Whitney
tests as appropriate. Seropositivity rates among Indigenous
patients according to age and gender were calculated using
the proportion of patients that tested positive for HTLV-1
within each category. Logistic regression with age category,
gender and age category X gender was used to assess the
influence of age on the difference in seropositivity rates ac-
cording to gender. The independent associations between
patient demographics and the odds of HTLV-1 infection
were assessed using binary logistic regression. In order to
assess whether the effects of STI were similar for the 3 dif-
ferent patient groups in our cohort we included a patient
group X interaction term in the logistic regression model
for HTLV-1 status. The interaction term was non-
significant and the associations between STI and HTLV-1
status were similar across the 3 groups. We therefore in-
cluded all patients in a single model and included a term
for group to adjust for the small differences in HTLV-1
prevalence across groups.
The proportion of seroconversions amongst those adults
tested twice was calculated as a proportion with binomial
95 % confidence intervals. Repeat testing for HTLV-1 in-
fection was ordered when clinically indicated by the treat-
ing physician and not as part of any scheduled clinical
monitoring program. Duration of follow-up in each case
was from the date of the initial negative serological test to
the date on which a positive test was recorded.
Results
The HTLV-1 serostatus was known for a total of 1889
patients of whom 1254 were HTLV-1 seronegative and
635 were HTLV-1 infected (HTLV-1 Western blot posi-
tive, 629; HTLV-1 Western blot indeterminate/HTLV-1
PCR positive, 6) (Fig. 2).
Risk factors for HTLV-1 infection
Patient demographics are detailed in Table 1. Infection
rates increased with age. Among 77 children who were
tested, one three year old boy was HTLV-1 infected.
However, only 29 of these children were from remote
communities in the west or south where risk of HTLV-1
infection was highest. The HTLV-1 infected child was
from the western quadrant (1 of 16 children tested,
6.25 %) and was confirmed HTLV-1 seroseropositive
after being admitted with intestinal strongyloidiasis.
Four of 41 adolescents (9.8 %) aged 15–17 years were
also HTLV-1 infected (male, 2; female, 2), including a
15 year old from a remote community in the western
quadrant who had been admitted in early childhood with
complicated strongyloidiasis and was subsequently found
to be HTLV-1 infected when he presented with respira-
tory failure complicating multi-lobar bronchiectasis. In
contrast, 611 of 1703 (35.9 %) adult residents of central
Australia were HTLV-1 seropositive. Seropositivity rates
among all adults continued to increase with age (Fig. 3)
(15–29 years, 17.3 %; 30–49 years, 36.2 %; 50–64 years,
41.7 %). Rates were similar between genders overall
(Table 1), however, seropositivity rates for men older
than 49 years were significantly higher than those for
women (men 50–64 years 48.5 % versus women 50–64
years, 37.2 %; men >65 years, 42.7 % versus women
>65 years, 34.6 %) (p = 0.04 for age category-by-gender
interaction) (Fig. 3).
Rates were lowest among residents of remote commu-
nities north of Alice Springs (12.6 %) and highest among
those from communities to the south (61.1 %) and west
(42.2 %). When compared according to residence type,
seropositivity rates were highest among town camp resi-
dents of Alice Springs (40.4 %) (Table 1). In a multivari-
able model, risk of HTLV-1 infection was significantly
reduced among urban residents of Alice Springs and res-
idents of Tennant Creek, a town in the Barkly region of
the Northern Territory (Fig 1), and increased among re-
mote residents of communities to the south and west of
Alice Springs (Table 2). In contrast, male gender and a
ten year increase in age independently increased the odds
of infection by approximately 40 % each (male gender, p =
0.01; age, p < 0.001). Men aged 50–64 years were twice
more likely than women of similar age to be HTLV-1 in-
fected after adjusting for region, gender and STI history
(OR = 2.4 (0.95, 6.18; p = 0.06).
There were no differences in HTLV-1 seropositivity
rates according to the reason for testing (Table 3).
Seropositivity rates for Groups 1, 2 and 3 were 33.3 %
(476/1431), 35.0 % (117/334) and 33.9 % (42/124), respect-
ively (p = 0.826). Similarly, there was no difference in rates
of infection between these groups after adjusting for age
and gender.
Other sexually transmitted infections
There were no differences between HTLV-1 seropositive
and seronegative groups in the proportion of patients
who tested positive for C.trachomatis and N.gonorrhoeae
NAAT (Table 1). However, syphilis serology was more
often positive among those who were HTLV-1 infected
(HTLV-1 seropositive, 59.4 %; HTLV-1 seronegative,
38.8 %) (p < 0.001) (Table 1) and having previously had
an STI was significantly associated with HTLV-1 infec-
tion in multivariable models (Table 2).
Horizontal transmission
Among 351 adults who were tested more than once dur-
ing a total of 1231 years at risk and under observation,
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two Indigenous women and one man (3/351, 0.85 %) ac-
quired HTLV-1 infection. The seroconversion rate in
this sub-group was therefore 0.24 per 100 person-years
(95 % CI = 0.18–2.48). Serodia PA were negative for both
women at ages 29 and 51 years, but positive results were
subsequently recorded and confirmed by Western blot
at 37 and 53 years, respectively. The man was HTLV-1
seronegative by serodia PA when 62 years old. A positive
result was recorded two years later at which time a
Western blot was indeterminate. He was finally con-
firmed to be HTLV-1 infected by HTLV-1 PCR at age
65 years. A review of medical records for each case failed
to reveal iatrogenic risk factors for acquiring HTLV-1 in-
fection, such as haemodialysis or a history of blood
transfusion.
Estimated infection risk among infants
Seropositivity rates among women of childbearing age
(15–40 years) varied according to their place of resi-
dence relative to Alice Springs (Table 4). The highest
rate was found among women residing in the southern
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Fig. 3 Graph of HTLV-1 seropositivity rates for Indigenous males and
females according to age among 1889 patients tested at Alice
Springs Hospital
Table 1 Demographics and patient characteristics for 1889 Indigenous patients admitted 2000-2013
No HTLV-1 (N = 1,254) HTLV-1 (N = 635) p-value
Age, years (±SD) 40.9 ± 17.3 47.4 ± 13.8 <0.001
Gender, n (%)
Female 670 (53.4) 327 (51.5)
Male 584 (46.6) 308 (48.5) 0.43
Residence, n (%)
Remotea 652 (52.0) 389 (61.3) <0.001
Town Campb 193 (15.4) 131 (20.6)
Urbanc 206 (16.4) 70 (11.0)
Nursing Home 42 (3.4) 22 (3.5)
Tennant Creek 132 (10.5) 13 (2.0)
Outside regiond 23 (1.8) 9 (1.4)
Missinge 6 (0.5) 1 (0.2)
Sexually Transmitted Infectionsf, n (%)
Syphilis 198 (38.6) 167 (59.4) <0.001
Tested 513 281
Gonorrhea 78 (18.9) 40 (15.9) 0.33
Tested 413 251
Chlamydia 51 (12.7) 24 (10.0) 0.31
Tested 401 240
Died, n (%) 270 (21.5) 163 (25.7) 0.04
Age at death, years (±SD) 53.0 ± 14.0 54.7 ± 13.3 0.21
Length of follow-up, years (±SD) 4.2 ± 2.9 4.6 ± 2.9 <0.001
aResidence in a remote community >80 km from Alice Springs, but not in the township of Tennant Creek
bResidence in a town camp in the Alice Springs township
cResidence in the Alice Springs township, but not in a town camp
dResidence outside the combined areas of central Australia and the adjacent Aboriginal lands of South Australia and Western Australia
ePlace of residence could not be ascertained
fAny positive test during the study period among subjects aged 15–45 years who were tested
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quadrant (49 %), the lowest among those from the
northern quadrant (7 %) and the mean for all quadrants
was 23 %. During a period of three years from 2010–
2012, 1289 Indigenous women delivered 1351 live in-
fants at ASH (mean (SD), 456 ± 19 infants per year). The
number of Indigenous infants who were potentially at
risk of mother-to-child HTLV-1 transmission was there-
fore 297 over the three years for which data was avail-
able (Table 4).
Discussion
In a large hospital-based cohort that included nearly 13 %
of Indigenous adult residents of central Australia, 35.9 %
of adults tested were HTLV-1 infected, corresponding to a
minimum period prevalence of 4.6 % based on 2006 re-
gional population estimates for central Australia and the
adjacent APY lands of South Australia (13,305 adults)
[17]. We also demonstrate considerable variability in
HTLV-1 seropositivity according to place of residence,
suggesting that rates may be substantially higher in some
communities. Micro-geographic variation in prevalence is
a feature of HTLV-1 epidemiology elsewhere [2]. In south-
western Japan, for example, seroprevalence rates exceed
30 % among adults in some villages, but are less than 10 %
in those nearby [18]. The virus is likely to be similarly con-
centrated within some isolated communities in central
Australia where HTLV-1c is thought to have been present
for ~9,000 years [3]. The HTLV-1 endemic area in
Australia is vast, extending from the far north of Western
Australia [6] to communities in South Australia some
1000 km away [5] and covering the entire ASH catchment
area of 1 million km2 [5, 16].
Table 2 Multivariable predictors of HTLV-1 infection among 1889 Indigenous patients
Model 1a Model 2a
Odds ratio 95 % CI p-value Odds ratio 95 % CI p-value
Age (years) 1.03 1.02–1.04 <0.001 1.04 1.04–1.03 <0.001
Gender (0 = F,1 = M) 1.18 0.97–1.45 0.10 1.42 1.09–1.86 0.01
Residenceb
Remotec 1.00
Town Campd 1.04 0.80–1.36 0.77
Urbane 0.59 0.43–0.80 0.001
N/H 0.56 0.32–0.98 0.04
Tennant Creek 0.17 0.09–0.31 <0.001
Outside regionf 0.65 0.29–1.45 0.29
Residence regiong
North 1.00
East 1.53 0.8–2.8 0.17
South 10.7 7.3–15.5 <0.001
West 4.4 3.1–6.2 <0.001
STIh 1.93 1.53–2.45 <0.001 1.42 1.04–1.97 0.036
Patient Group STI interactioni
Group 1 (n = 1431) 1.00 1.00
Group 2 (n = 334) 0.80 0.60–1.05 0.11 0.99 0.71–1.39 0.95
Group 3 (n = 124) 0.89 0.60–1.34 0.59 0.71 0.39–1.28 0.26
Abbreviations: N/H residence in a nursing home, STI sexually transmitted infections
aThe independent effects of residence and residence region were assessed separately in order to avoid posssible colinearity
bIncluding 1882 subjects whose place of residence was known
cResidence in a remote community >80 km from Alice Springs, but not in the township of Tennant Creek
dResidence in a town camp in the Alice Springs township
eResidence in Alice Springs township, but not in a town camp
fResidence outside the combined areas of central Australia and the adjacent Aboriginal lands of South Australia and Western Australia
gIncluding 1233 subjects who resided in remote communities categorized according to quadrants relative to Alice Springs
hAny positive test during the study period among subjects aged 15–45 years who were tested
iReasons for HTLV-1 testing included: a) to investigate the cause of conditions thought to be HTLV-1 associated (Group 1, n = 1431), b) as part of a blood borne
virus surveillance program among patients receiving haemodialysis (Group 2, n = 334) and c) after enrollment as subjects without current clinical evidence of
HTLV-1 associated conditions in HTLV-1 pathogenesis studies (Group 3, n = 124). To demonstrate that these groups can be combined for the purposes of analysis, we
determined whether there was a difference in the association between HTLV-1 and STI across groups using a Group x STI interaction term. This was non-significant,
indicating that the estimated association with STI is the same across all groups, which were therefore combined for analysis. Data for HTLV-1 serostatus according to
age and gender for each group is presented in Table 3
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Consistent with studies in other endemic areas [1, 15,
18–23], the risk of HTLV-1 infection among Indigenous
Australians increased substantially with age. Elsewhere,
rates among women are typically higher than those for
men due to a gender-based difference in sexual trans-
mission that is thought to result from the close cell asso-
ciation of the virus [18, 19]. Thus, incidence rates for
men and women living in discordant heterosexual rela-
tionships are 1.2 and 4.9 per 100 person-years, respect-
ively [24]. Infection rates among women increase with
age and are typically higher than those for men, presum-
ably reflecting a heightened risk of transmission that ac-
companies physiological changes in the female genital
tract [25]. In contrast, central Australian men were more
likely to be HTLV-1 infected than women of similar age.
An increased risk of HTLV-1 infection among men
relative to women has not been described previously; how-
ever, ornamental scarification increases risk of HTLV-1 in-
fection in Guinea-Bissau [26]. Similar cultural practices in
central Australia have largely been confined to men in the
context of initiation rites, which may have resulted in
blood contact between participants in the past [27]. Modi-
fications to these practices and the introduction of single-
use blades may have contributed to a cohort effect among
men in the present study.
Sexual transmission is also likely in central Australia.
Higher numbers of sexual partners [28–32] and a longer
sexual relationship with a partner at risk of HTLV-1 in-
fection [33] predict HTLV-1 infection. Incidence rates of
HTLV-1 infection in other HTLV-1 endemic areas are
therefore higher among commercial sex workers (0.7 per
100 person years) [34] and subjects attending sexual
Table 4 Estimated numbers of infants born to HTLV-1 infected mothers, 2010-2012
Maternal residence Live infants HTLV-1 infected women (15–40 years) Infants at riskb
WB+/testeda %
Remotec
North 273 6/88 7 19
East 98 3/22 14 14
South 167 26/53 49 82
West 260 22/99 23 60
Alice Springsd 422 38/132 29 122
Tennant Creeke 131 0/21 0 0
Totalf 1351 95/415 23 297
Abbreviations: HTLV-1, infection with the Human T-Lymphotropic Virus type 1, WB+ western blot positive
aThe number of women aged 15–40 years who tested positive for HTLV-1 infection divided by the number tested
bThe number of infants at risk of mother-to-child HTLV-1 infection was calculated by multiplying the estimated number of HTLV-1 infected women aged 15–40
years by the number of live infants whose mothers resided in each location
cResidence in a remote community according to quadrant relative to Alice Springs
dAny residence in the Alice Springs township
eResidence in the township of Tennant Creek
fExcluding 3 infants born to women from outside the region and 1 whose place of residence could not be ascertained
Table 3 HTLV-1 seropositivity rates stratified by age and gender according to reason for testing
Age categories (years) HTLV-1+/n (%)
0–14 15–29 30–49 50–64 65+
Female
Group 1 (n = 760) 0/36 (0.0) 32/150 (21.3) 125/341 (36.7) 63/157 (40.1) 30/76 (39.5)
Group 2 (n = 173) 0 1/7 (14.3) 22/64 (34.4) 23/79 (29.1) 6/23 (26.1)
Group 3 (n = 64) 0 0/7 (0.0) 13/26 (50.0) 11/22 (50.0) 1/9 (11.1)
Male
Group 1 (n = 671) 1/37 (2.7) 16/114 (14.0) 132/341 (38.7) 48/117 (41.0) 29/62 (46.8)
Group 2 (n = 161) 0 2/9 (22.2) 20/77 (26.0) 39/64 (60.9) 4/11 (36.4)
Group 3 (n = 60) 0/1 (0.0) 1/10 (10.0) 6/28 (21.4) 9/17 (52.9) 1/4 (25.0)
HTLV-1 seropositivity rates for the various age categories for male and female Indigenous patients according to reason for testing. Subjects were tested: a) to
investigate the cause of conditions that are thought to be associated with HTLV-1 infection (Group 1, n = 1431), b) as part of a blood borne virus (BBV) surveillance
program among patients receiving haemodialysis (Group 2, n = 334) and c) after enrollment as subjects without current clinical evidence of HTLV-1 associated
conditions in HTLV-1 pathogenesis studies (Group 3, n = 124). Seropositivity rates increase with age for both males and females irrespective of the reason for
testing and in each group rates among men aged greater than 65 years exceed those for women of comparable age
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health clinics (0.8–0.9 per 100 person-years) [29, 35]
relative to the general public (0.09–0.19 per 100 person-
years) [36–38]. The seroconversion rate recorded by us
for a subset of our adult cohort (0.24 per 100 person-
years) was therefore somewhat higher than incidence
rates in the general public elsewhere. However, we were
unable to repeat HTLV-1 serological tests for most sub-
jects and this seroconversion rate may not reflect the
true HTLV-1 incidence rate among Indigenous adults in
central Australia. The association between STI history
and HTLV-1 infection reported here is supported by
previous studies. The risk of acquiring HTLV-1 infection
is enhanced by the presence of genital lesions [39] and
STIs, including syphilis [29, 39] and gonorrhea [29].
High regional STI incidence rates [40, 41] are therefore
likely to increase the risk of sexually acquired HTLV-1
infection in central Australia.
We also document childhood infection, which is likely
to be responsible for the cases of ATLL [4] and infective
dermatitis [8] that have recently been reported from
central Australia. Early childhood infection typically re-
sults from the continued exposure of infants to HTLV-1
infected cells in breast milk [15] after the loss of protect-
ive maternal antibodies, which occurs at a mean postna-
tal age of eleven months [42]. Consequently, infection
rates increase substantially with the duration of breast-
feeding; 3.9–7.4 % at 6–7 months, [15, 42–45]; 14.4–
20.3 % after 6 months [15, 43, 45] and 32 % if breast
feeding is continued longer than 12 months [42]. Indi-
genous Australian children are often breast-fed for sev-
eral years [46], long after the loss of protective maternal
antibodies. In resource-limited settings, weaning within
6 months has been advocated as a means of reducing
risk of mother-to-child HTLV-1 transmission [43, 47,
48]. Although this approach has been criticized due to
concerns that infection-related infant mortality may be
increased in resource limited countries [49], incidence
rates have decreased where breast-feeding by HTLV-1
infected mothers has been restricted in other settings. In
Japan, for example, HTLV-1 infected mothers are ad-
vised not to breast feed [15, 50] or to do so for
<3 months [50], a strategy that has been accompanied
by a marked fall in the incidence rates of HTLV-1 infec-
tion. The safe implementation of a program to prevent
mother-to-child transmission of HTLV-1 by providing
women with appropriate education, infant formula and
lactation inhibitors has also recently been reported from
Brazil [51]. In contrast, Government agencies that are
responsible for public health in Australia have not intro-
duced any coordinated strategy to reduce the risk of
HTLV-1 transmission to Indigenous children. HTLV-1
testing is not included in routine antenatal screening in
central Australia [13] and there is no health literacy pro-
gram by which Indigenous mothers can be informed of
the potential risks posed by HTLV-1 infection to their
children.
The retrospective design and hospital-based setting for
this study results in a number of limitations. Firstly, our
data is derived from a large cohort of hospitalized sub-
jects for whom HTLV-1 serology was most often
requested for clinical reasons. The resulting seropositiv-
ity rates are therefore subject to selection bias and
community-based prevalence may be lower. The absence
of any difference in HTLV-1 seropositivity between pa-
tients tested for clinical reasons and those who were re-
cruited as asymptomatic controls is likely to reflect the
fact that most HTLV-1 tests at ASH are ordered to ac-
company strongyloides serology [5]. The purpose of this
practice is to identify HTLV-1/S.stercoralis coinfected
subjects who require closer follow-up. We have previ-
ously demonstrated that only 36 % of such patients are
HTLV-1 infected and that strongyloides seropositivity is
not associated with HTLV-1 serostatus [5], presumably
because the risk of exposure to S.stercoralis in commu-
nities with poor sanitation is independent of HTLV-1 in-
fection. Selection bias is also likely to affect our estimate
of the number of infants at risk because this was extrapo-
lated from seropositivity rates for hospitalized women of
childbearing age, which may over-estimate community-
based HTLV-1 prevalence in this group. The number of
children at risk of mother-to-child HTLV-1 transmission
may therefore be less than our estimate of 297 children
over three years or 99 children per year. We are also un-
able to determine the modes of HTLV-1 transmission for
childhood infection or for those adults whose seroconver-
sion was documented later in life. However, the literature
suggests that vertical transmission is most likely to ac-
count for the former [15, 42, 43] and sexual transmission
for the latter [1, 19, 29, 33].
Conclusion
In a hospital-based cohort, we report childhood HTLV-1
infection that is suggestive of mother-to-child transmis-
sion, an increased risk of infection among older men
that may reflect past cultural practices and document
horizontal transmission that is likely to result from sex-
ual contact. Community-based epidemiological studies
are now needed to determine the true HTLV-1 preva-
lence and to define the relative contributions of the vari-
ous modes of transmission. However, our findings
suggest that multiple modes of transmission are likely to
contribute to the high prevalence of HTLV-1 infection
among Indigenous Australians. The development of any
intervention to control HTLV-1 transmission therefore
requires careful community engagement, cultural under-
standing and Indigenous leadership. High seropositivity
rates [5], significant morbidity [4, 5] and evidence of sex-
ual transmission also argue for the inclusion of this virus
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in the National Aboriginal and Torres Strait Islander
BBV and STI Strategy [52]. Unfortunately, in the
quarter-century since HTLV-1 was first shown to be en-
demic to central Australia, there has been no systematic
attempt to provide Indigenous Australians with informa-
tion about this infection. Developing the necessary
health literacy required to implement any strategy to
prevent HTLV-1 transmission therefore remains a con-
siderable challenge.
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